RxDoctor Payments Data

Lori Gibbons

Adult Health · Sebastian, FLNPI 1689804023

Payments from drug & device makers

$816in general payments, 2019–2025

Across 29 payments — averaging $28.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$137
  • Medtronic$126
  • Abbott$119
  • Amgen$118
  • Dexcom, Inc.$65
  • AbbVie$63
  • plus $188 from 8 others

What the payments were for

  • Food & beverage$816100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$816 in reported general payments places this provider in the 55th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$127,318
Medicare patients
472
Services billed
1,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide195$286,157
EliquisApixaban96$121,755
MounjaroTirzepatide64$87,250
XareltoRivaroxaban30$39,389
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$38,421
RybelsusSemaglutide27$37,834
JanuviaSitagliptin Phosphate23$34,636
ProliaDenosumab20$33,986
FarxigaDapagliflozin Propanediol16$26,015
TrulicityDulaglutide13$24,661
EntrestoSacubitril/Valsartan12$21,537
TradjentaLinagliptin13$16,672
Repatha SureclickEvolocumab11$11,749
Atorvastatin Calcium592$7,468
Lantus SolostarInsulin Glargine,hum.Rec.Anlog38$7,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$61$323,992222 claims
Lilly USA, LLCMounjaro, Trulicity$35$111,91177 claims
Johnson & JohnsonXarelto$137$39,38930 claims
AmgenProlia$118$33,98620 claims
AbbVieSynthroid$63$4,05356 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,237 adult health providers in Florida.

Other adult health in Sebastian

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →